Efficacy and Safety of CT‐P43, a Candidate Ustekinumab Biosimilar, in Moderate‐to‐Severe Plaque Psoriasis: 52‐Week Results From a Randomised, Active‐Controlled, Double‐Blind, Phase III Study.
Saved in:
| Title: | Efficacy and Safety of CT‐P43, a Candidate Ustekinumab Biosimilar, in Moderate‐to‐Severe Plaque Psoriasis: 52‐Week Results From a Randomised, Active‐Controlled, Double‐Blind, Phase III Study. |
|---|---|
| Authors: | Papp, Kim A.1,2 (AUTHOR), Jaworski, Janusz3 (AUTHOR), Kwiek, Bartlomiej4 (AUTHOR), Trefler, Jakub5 (AUTHOR), Dudek, Anna6 (AUTHOR), Szepietowski, Jacek C.7,8 (AUTHOR), Reznichenko, Nataliya9 (AUTHOR), Narbutt, Joanna10 (AUTHOR), Baran, Wojciech11 (AUTHOR), Kolinek, Joanna12 (AUTHOR), Daniluk, Stefan12 (AUTHOR), Bartnicka-Maslowska, Katarzyna13 (AUTHOR), Reich, Adam14 (AUTHOR), Andrashko, Yuriy15 (AUTHOR), Kim, Sunghyun16 (AUTHOR), Bae, Yunju16 (AUTHOR), Jeon, Dabee16 (AUTHOR), Jung, Jinsun16 (AUTHOR), Lee, Hyunseung16 (AUTHOR), Ko, Woori16 (AUTHOR) |
| Source: | Dermatologic Therapy. 2/23/2026, Vol. 2026, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 13960296 |
|---|---|
| DOI: | 10.1155/dth/8811546 |
